## Table S1: Associations between isoprostanes and growth measures at 14 months

| Urinary oxidative stress biomarker | Outcome | N | 25th Percentile | 75th Percentile | Outcome, 75th Percentile v. 25th Percentile | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Predicted Outcome at 25th Percentile | Predicted Outcome at 75th Percentile | Coefficient (95% CI) | P-value |
| IPF(2a)-III | LAZ Year 1 | 676 | -0.72 | -0.09 | -1.27 | -1.4 | -0.13 (-0.21, -0.06) | 0\*\* |
|  | WAZ Year 1 | 577 | -0.73 | -0.09 | -1.14 | -1.29 | -0.14 (-0.22, -0.06) | 0\*\* |
|  | WLZ Year 1 | 578 | -0.73 | -0.09 | -0.75 | -0.86 | -0.12 (-0.2, -0.04) | 0\* |
|  | HCZ Year 1 | 673 | -0.72 | -0.1 | -1.64 | -1.66 | -0.02 (-0.1, 0.05) | 0.51 |
|  |  |  |  |  |  |  |  |  |
| 2,3-dinor-iPF(2a)-III | LAZ Year 1 | 676 | 1.55 | 1.97 | -1.23 | -1.42 | -0.19 (-0.3, -0.07) | 0\* |
|  | WAZ Year 1 | 577 | 1.55 | 1.97 | -1.18 | -1.23 | -0.05 (-0.26, 0.16) | 0.63 |
|  | WLZ Year 1 | 578 | 1.54 | 1.97 | -0.78 | -0.77 | 0.01 (-0.21, 0.23) | 0.93 |
|  | HCZ Year 1 | 673 | 1.55 | 1.97 | -1.67 | -1.7 | -0.02 (-0.17, 0.12) | 0.75 |
|  |  |  |  |  |  |  |  |  |
| iPF(2a)-VI | LAZ Year 1 | 676 | 2.31 | 2.87 | -1.23 | -1.45 | -0.22 (-0.35, -0.1) | 0\*\* |
|  | WAZ Year 1 | 577 | 2.3 | 2.87 | -1.08 | -1.19 | -0.12 (-0.21, -0.03) | 0.01\* |
|  | WLZ Year 1 | 578 | 2.3 | 2.87 | -0.74 | -0.8 | -0.07 (-0.16, 0.02) | 0.13 |
|  | HCZ Year 1 | 673 | 2.3 | 2.87 | -1.63 | -1.66 | -0.03 (-0.13, 0.07) | 0.59 |
|  |  |  |  |  |  |  |  |  |
| 8,12-iso-iPF(2a)-VI | LAZ Year 1 | 676 | 2.17 | 2.92 | -1.22 | -1.33 | -0.11 (-0.23, 0.02) | 0.09 |
|  | WAZ Year 1 | 577 | 2.19 | 2.91 | -1.04 | -1.17 | -0.13 (-0.25, 0) | 0.04 |
|  | WLZ Year 1 | 578 | 2.19 | 2.91 | -0.72 | -0.8 | -0.08 (-0.18, 0.03) | 0.14 |
|  | HCZ Year 1 | 673 | 2.16 | 2.92 | -1.63 | -1.65 | -0.02 (-0.14, 0.1) | 0.76 |
|  |  |  |  |  |  |  |  |  |
| Combined urinary oxidative stress biomarkers | LAZ Year 1 | 676 | 2.49 | 3.54 | -1.16 | -1.47 | -0.31 (-0.51, -0.11) | 0\* |
|  | WAZ Year 1 | 577 | 2.5 | 3.55 | -1.12 | -1.3 | -0.18 (-0.27, -0.08) | 0\*\* |
|  | WLZ Year 1 | 578 | 2.49 | 3.54 | -0.73 | -0.85 | -0.12 (-0.21, -0.02) | 0.01 |
|  | HCZ Year 1 | 673 | 2.48 | 3.54 | -1.63 | -1.67 | -0.04 (-0.15, 0.07) | 0.46 |
| N, 25th Percentile, and 75th Percentile are from the adjusted analyses | | | | | | | | |
| \* P-value < 0.05 after FDR correction (\*\* P-value < 0.01, \*\*\* P-value < 0.001) | | | | | | | | |

## Table S2: Associations between isoprostanes and growth measures at 28 months

| Urinary oxidative stress biomarker | Outcome | N | 25th Percentile | 75th Percentile | Outcome, 75th Percentile v. 25th Percentile | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Predicted Outcome at 25th Percentile | Predicted Outcome at 75th Percentile | Coefficient (95% CI) | P-value |
| IPF(2a)-III | LAZ Year 2 | 578 | -0.73 | -0.09 | -1.6 | -1.59 | 0.01 (-0.03, 0.05) | 0.58 |
|  | WAZ Year 2 | 576 | -0.73 | -0.09 | -1.66 | -1.61 | 0.04 (0, 0.09) | 0.05 |
|  | WLZ Year 2 | 597 | -0.73 | -0.09 | -1.24 | -1.18 | 0.06 (0, 0.11) | 0.04 |
|  | HCZ Year 2 | 595 | -0.73 | -0.09 | -1.98 | -1.94 | 0.04 (-0.01, 0.09) | 0.09 |
|  |  |  |  |  |  |  |  |  |
| 2,3-dinor-iPF(2a)-III | LAZ Year 2 | 578 | 1.54 | 1.97 | -1.61 | -1.57 | 0.04 (-0.01, 0.09) | 0.13 |
|  | WAZ Year 2 | 576 | 1.55 | 1.97 | -1.67 | -1.63 | 0.04 (-0.03, 0.1) | 0.25 |
|  | WLZ Year 2 | 597 | 1.54 | 1.97 | -1.22 | -1.18 | 0.04 (-0.05, 0.12) | 0.42 |
|  | HCZ Year 2 | 595 | 1.54 | 1.97 | -1.99 | -1.93 | 0.06 (0.01, 0.11) | 0.03 |
|  |  |  |  |  |  |  |  |  |
| iPF(2a)-VI | LAZ Year 2 | 578 | 2.3 | 2.87 | -1.61 | -1.57 | 0.05 (-0.02, 0.11) | 0.18 |
|  | WAZ Year 2 | 576 | 2.3 | 2.87 | -1.66 | -1.63 | 0.03 (-0.01, 0.08) | 0.16 |
|  | WLZ Year 2 | 597 | 2.3 | 2.86 | -1.22 | -1.18 | 0.04 (-0.02, 0.1) | 0.19 |
|  | HCZ Year 2 | 595 | 2.3 | 2.87 | -2 | -1.94 | 0.05 (-0.02, 0.12) | 0.14 |
|  |  |  |  |  |  |  |  |  |
| 8,12-iso-iPF(2a)-VI | LAZ Year 2 | 578 | 2.19 | 2.91 | -1.66 | -1.57 | 0.09 (-0.02, 0.2) | 0.1 |
|  | WAZ Year 2 | 576 | 2.19 | 2.91 | -1.66 | -1.64 | 0.03 (-0.02, 0.07) | 0.33 |
|  | WLZ Year 2 | 597 | 2.17 | 2.91 | -1.23 | -1.19 | 0.04 (-0.02, 0.1) | 0.2 |
|  | HCZ Year 2 | 595 | 2.17 | 2.9 | -2 | -1.94 | 0.06 (-0.01, 0.12) | 0.12 |
|  |  |  |  |  |  |  |  |  |
| Combined urinary oxidative stress biomarkers | LAZ Year 2 | 578 | 2.49 | 3.53 | -1.6 | -1.57 | 0.03 (-0.06, 0.13) | 0.51 |
|  | WAZ Year 2 | 576 | 2.5 | 3.54 | -1.61 | -1.64 | -0.04 (-0.16, 0.09) | 0.57 |
|  | WLZ Year 2 | 597 | 2.49 | 3.53 | -1.2 | -1.18 | 0.02 (-0.14, 0.18) | 0.81 |
|  | HCZ Year 2 | 595 | 2.48 | 3.53 | -1.99 | -1.93 | 0.06 (0, 0.11) | 0.05 |
| N, 25th Percentile, and 75th Percentile are from the adjusted analyses | | | | | | | | |
| \* P-value < 0.05 after FDR correction (\*\* P-value < 0.01, \*\*\* P-value < 0.001) | | | | | | | | |

## Table S3: Associations between isoprostanes and growth velocity measures

| Urinary oxidative stress biomarker | Outcome | N | 25th Percentile | 75th Percentile | Outcome, 75th Percentile v. 25th Percentile | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Predicted Outcome at 25th Percentile | Predicted Outcome at 75th Percentile | Coefficient (95% CI) | P-value |
| IPF(2a)-III | Length velocity (cm/month) Year 1 to Year 2 | 577 | -0.73 | -0.09 | 0.78 | 0.78 | 0 (-0.01, 0.01) | 0.78 |
|  | Weight velocity (kg/month) Year 1 to Year 2 | 601 | -0.73 | -0.09 | 0.14 | 0.15 | 0 (0, 0.01) | 0.03 |
|  | Head circumference velocity (cm/month) Year 1 to Year 2 | 584 | -0.73 | -0.09 | 0.15 | 0.15 | 0 (0, 0.01) | 0.16 |
|  |  |  |  |  |  |  |  |  |
| 2,3-dinor-iPF(2a)-III | Length velocity (cm/month) Year 1 to Year 2 | 577 | 1.54 | 1.97 | 0.79 | 0.79 | 0.01 (0, 0.02) | 0.12 |
|  | Weight velocity (kg/month) Year 1 to Year 2 | 601 | 1.54 | 1.97 | 0.14 | 0.15 | 0 (0, 0.01) | 0.13 |
|  | Head circumference velocity (cm/month) Year 1 to Year 2 | 584 | 1.54 | 1.97 | 0.15 | 0.16 | 0.01 (0, 0.01) | 0.04 |
|  |  |  |  |  |  |  |  |  |
| iPF(2a)-VI | Length velocity (cm/month) Year 1 to Year 2 | 577 | 2.3 | 2.87 | 0.78 | 0.79 | 0.01 (-0.01, 0.02) | 0.3 |
|  | Weight velocity (kg/month) Year 1 to Year 2 | 601 | 2.3 | 2.86 | 0.14 | 0.15 | 0 (0, 0.01) | 0.11 |
|  | Head circumference velocity (cm/month) Year 1 to Year 2 | 584 | 2.3 | 2.87 | 0.15 | 0.16 | 0 (0, 0.01) | 0.3 |
|  |  |  |  |  |  |  |  |  |
| 8,12-iso-iPF(2a)-VI | Length velocity (cm/month) Year 1 to Year 2 | 577 | 2.19 | 2.91 | 0.78 | 0.79 | 0.02 (-0.01, 0.04) | 0.2 |
|  | Weight velocity (kg/month) Year 1 to Year 2 | 601 | 2.16 | 2.9 | 0.14 | 0.15 | 0 (0, 0.01) | 0.39 |
|  | Head circumference velocity (cm/month) Year 1 to Year 2 | 584 | 2.18 | 2.91 | 0.15 | 0.16 | 0.01 (0, 0.02) | 0.2 |
|  |  |  |  |  |  |  |  |  |
| Combined urinary oxidative stress biomarkers | Length velocity (cm/month) Year 1 to Year 2 | 577 | 2.49 | 3.53 | 0.79 | 0.79 | 0 (-0.02, 0.03) | 0.79 |
|  | Weight velocity (kg/month) Year 1 to Year 2 | 601 | 2.49 | 3.52 | 0.15 | 0.15 | 0 (-0.01, 0.01) | 0.56 |
|  | Head circumference velocity (cm/month) Year 1 to Year 2 | 584 | 2.47 | 3.53 | 0.15 | 0.16 | 0.01 (0, 0.01) | 0.11 |
| N, 25th Percentile, and 75th Percentile are from the adjusted analyses | | | | | | | | |
| \* P-value < 0.05 after FDR correction (\*\* P-value < 0.01, \*\*\* P-value < 0.001) | | | | | | | | |

## Table S4: Associations between isoprostanes and change in growth Z-score

| Urinary oxidative stress biomarker | Outcome | N | 25th Percentile | 75th Percentile | Outcome, 75th Percentile v. 25th Percentile | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Predicted Outcome at 25th Percentile | Predicted Outcome at 75th Percentile | Coefficient (95% CI) | P-value |
| IPF(2a)-III | Change in LAZ from Year 1 to Year 2 | 581 | -0.73 | -0.09 | -0.25 | -0.23 | 0.02 (-0.03, 0.06) | 0.45 |
|  | Change in WAZ from Year 1 to Year 2 | 601 | -0.73 | -0.09 | -0.39 | -0.31 | 0.08 (0.04, 0.13) | 0\*\* |
|  | Change in WLZ from Year 1 to Year 2 | 577 | -0.73 | -0.09 | -0.22 | -0.11 | 0.11 (0.05, 0.18) | 0\*\* |
|  | Change in HCZ from Year 1 to Year 2 | 581 | -0.73 | -0.09 | -0.17 | -0.13 | 0.04 (-0.01, 0.09) | 0.14 |
|  |  |  |  |  |  |  |  |  |
| 2,3-dinor-iPF(2a)-III | Change in LAZ from Year 1 to Year 2 | 581 | 1.54 | 1.97 | -0.23 | -0.15 | 0.09 (0.03, 0.14) | 0\* |
|  | Change in WAZ from Year 1 to Year 2 | 601 | 1.54 | 1.97 | -0.4 | -0.34 | 0.07 (0, 0.13) | 0.04 |
|  | Change in WLZ from Year 1 to Year 2 | 577 | 1.54 | 1.97 | -0.2 | -0.19 | 0.02 (-0.1, 0.14) | 0.8 |
|  | Change in HCZ from Year 1 to Year 2 | 581 | 1.54 | 1.97 | -0.18 | -0.11 | 0.07 (0.01, 0.13) | 0.02 |
|  |  |  |  |  |  |  |  |  |
| iPF(2a)-VI | Change in LAZ from Year 1 to Year 2 | 581 | 2.3 | 2.87 | -0.29 | -0.17 | 0.12 (0.03, 0.21) | 0.01\* |
|  | Change in WAZ from Year 1 to Year 2 | 601 | 2.3 | 2.86 | -0.43 | -0.37 | 0.07 (0.02, 0.12) | 0.01\* |
|  | Change in WLZ from Year 1 to Year 2 | 577 | 2.3 | 2.87 | -0.22 | -0.18 | 0.05 (-0.06, 0.15) | 0.38 |
|  | Change in HCZ from Year 1 to Year 2 | 581 | 2.3 | 2.87 | -0.2 | -0.13 | 0.07 (-0.01, 0.15) | 0.1 |
|  |  |  |  |  |  |  |  |  |
| 8,12-iso-iPF(2a)-VI | Change in LAZ from Year 1 to Year 2 | 581 | 2.19 | 2.91 | -0.24 | -0.15 | 0.09 (-0.02, 0.2) | 0.1 |
|  | Change in WAZ from Year 1 to Year 2 | 601 | 2.16 | 2.9 | -0.4 | -0.34 | 0.06 (0.01, 0.12) | 0.03 |
|  | Change in WLZ from Year 1 to Year 2 | 577 | 2.19 | 2.91 | -0.22 | -0.15 | 0.07 (0, 0.14) | 0.05 |
|  | Change in HCZ from Year 1 to Year 2 | 581 | 2.18 | 2.91 | -0.19 | -0.13 | 0.06 (-0.01, 0.14) | 0.11 |
|  |  |  |  |  |  |  |  |  |
| Combined urinary oxidative stress biomarkers | Change in LAZ from Year 1 to Year 2 | 581 | 2.49 | 3.53 | -0.25 | -0.19 | 0.06 (-0.04, 0.16) | 0.25 |
|  | Change in WAZ from Year 1 to Year 2 | 601 | 2.49 | 3.52 | -0.4 | -0.31 | 0.09 (0.04, 0.14) | 0\*\* |
|  | Change in WLZ from Year 1 to Year 2 | 577 | 2.49 | 3.53 | -0.16 | -0.11 | 0.05 (-0.12, 0.23) | 0.57 |
|  | Change in HCZ from Year 1 to Year 2 | 581 | 2.47 | 3.53 | -0.18 | -0.12 | 0.06 (0, 0.12) | 0.06 |
| N, 25th Percentile, and 75th Percentile are from the adjusted analyses | | | | | | | | |
| \* P-value < 0.05 after FDR correction (\*\* P-value < 0.01, \*\*\* P-value < 0.001) | | | | | | | | |

## Table S5: Associations between salivary biomarkers and growth measures at 28 months

| Salivary stress biomarker | Outcome | N | 25th Percentile | 75th Percentile | Outcome, 75th Percentile v. 25th Percentile | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Predicted Outcome at 25th Percentile | Predicted Outcome at 75th Percentile | Coefficient (95% CI) | P-value |
| Pre-stressor cortisol | LAZ Year 2 | 700 | -2.51 | -1.66 | -1.6 | -1.52 | 0.08 (-0.03, 0.2) | 0.17 |
|  | WAZ Year 2 | 700 | -2.51 | -1.66 | -1.81 | -1.76 | 0.05 (-0.07, 0.17) | 0.4 |
|  | WLZ Year 2 | 711 | -2.51 | -1.66 | -1.17 | -1.18 | 0 (-0.09, 0.08) | 0.94 |
|  | HCZ Year 2 | 740 | -2.51 | -1.66 | -1.7 | -1.71 | -0.01 (-0.09, 0.06) | 0.78 |
|  |  |  |  |  |  |  |  |  |
| Post-stressor cortisol | LAZ Year 2 | 651 | -2.06 | -0.61 | -1.6 | -1.57 | 0.03 (-0.05, 0.1) | 0.46 |
|  | WAZ Year 2 | 651 | -2.06 | -0.61 | -1.73 | -1.69 | 0.03 (-0.13, 0.2) | 0.7 |
|  | WLZ Year 2 | 660 | -2.06 | -0.6 | -1.05 | -1.07 | -0.02 (-0.2, 0.17) | 0.88 |
|  | HCZ Year 2 | 687 | -2.06 | -0.61 | -1.73 | -1.75 | -0.02 (-0.16, 0.12) | 0.82 |
|  |  |  |  |  |  |  |  |  |
| Pre to post-stress change in cortisol | LAZ Year 2 | 645 | 0 | 0.01 | -1.65 | -1.62 | 0.03 (-0.02, 0.08) | 0.25 |
|  | WAZ Year 2 | 645 | 0 | 0.01 | -1.78 | -1.81 | -0.03 (-0.16, 0.11) | 0.71 |
|  | WLZ Year 2 | 654 | 0 | 0.01 | -1.13 | -1.2 | -0.07 (-0.22, 0.08) | 0.37 |
|  | HCZ Year 2 | 681 | 0 | 0.01 | -1.65 | -1.62 | 0.03 (-0.07, 0.13) | 0.61 |
|  |  |  |  |  |  |  |  |  |
| Cortisol residualized gain score | LAZ Year 2 | 645 | -0.21 | 0.14 | -1.65 | -1.62 | 0.03 (-0.02, 0.08) | 0.24 |
|  | WAZ Year 2 | 645 | -0.21 | 0.14 | -1.77 | -1.83 | -0.06 (-0.13, 0.01) | 0.08 |
|  | WLZ Year 2 | 654 | -0.21 | 0.14 | -1.12 | -1.23 | -0.11 (-0.19, -0.02) | 0.01 |
|  | HCZ Year 2 | 681 | -0.21 | 0.14 | -1.7 | -1.67 | 0.03 (-0.08, 0.13) | 0.62 |
|  |  |  |  |  |  |  |  |  |
| Pre-stressor sAA | LAZ Year 2 | 695 | 3.48 | 4.64 | -1.56 | -1.53 | 0.03 (-0.11, 0.17) | 0.7 |
|  | WAZ Year 2 | 695 | 3.48 | 4.64 | -1.79 | -1.8 | -0.01 (-0.07, 0.05) | 0.74 |
|  | WLZ Year 2 | 706 | 3.48 | 4.64 | -1.21 | -1.21 | 0 (-0.13, 0.13) | 0.98 |
|  | HCZ Year 2 | 735 | 3.47 | 4.63 | -1.68 | -1.69 | -0.01 (-0.07, 0.05) | 0.84 |
|  |  |  |  |  |  |  |  |  |
| Post-stressor sAA | LAZ Year 2 | 668 | 3.89 | 5.15 | -1.55 | -1.53 | 0.02 (-0.04, 0.08) | 0.6 |
|  | WAZ Year 2 | 668 | 3.89 | 5.15 | -1.75 | -1.74 | 0.02 (-0.04, 0.08) | 0.55 |
|  | WLZ Year 2 | 678 | 3.89 | 5.15 | -1.28 | -1.19 | 0.09 (-0.07, 0.25) | 0.29 |
|  | HCZ Year 2 | 703 | 3.88 | 5.11 | -1.69 | -1.68 | 0.01 (-0.05, 0.07) | 0.73 |
|  |  |  |  |  |  |  |  |  |
| Pre to post-stress change in sAA | LAZ Year 2 | 656 | -0.08 | 4.44 | -1.63 | -1.53 | 0.1 (-0.04, 0.23) | 0.16 |
|  | WAZ Year 2 | 656 | -0.08 | 4.44 | -1.77 | -1.77 | 0 (-0.03, 0.04) | 0.87 |
|  | WLZ Year 2 | 666 | -0.08 | 4.43 | -1.19 | -1.2 | -0.01 (-0.05, 0.03) | 0.75 |
|  | HCZ Year 2 | 691 | -0.08 | 4.33 | -1.67 | -1.68 | -0.01 (-0.04, 0.03) | 0.72 |
|  |  |  |  |  |  |  |  |  |
| sAA residualized gain score | LAZ Year 2 | 657 | -51.4 | 30.95 | -1.6 | -1.53 | 0.08 (-0.05, 0.2) | 0.23 |
|  | WAZ Year 2 | 657 | -51.4 | 30.95 | -1.78 | -1.78 | 0 (-0.04, 0.04) | 0.97 |
|  | WLZ Year 2 | 667 | -51.4 | 30.33 | -1.2 | -1.21 | -0.01 (-0.06, 0.03) | 0.6 |
|  | HCZ Year 2 | 692 | -51.41 | 26.51 | -1.67 | -1.68 | -0.02 (-0.05, 0.02) | 0.42 |
| N, 25th Percentile, and 75th Percentile are from the adjusted analyses | | | | | | | | |
| \* P-value < 0.05 after FDR correction (\*\* P-value < 0.01, \*\*\* P-value < 0.001) | | | | | | | | |

## Table S6: Associations between sympathetic-adreno-medullar biomarkers and growth measures at 28 months

| Resting SAM biomarker | Outcome | N | 25th Percentile | 75th Percentile | Outcome, 75th Percentile v. 25th Percentile | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Predicted Outcome at 25th Percentile | Predicted Outcome at 75th Percentile | Coefficient (95% CI) | P-value |
| Mean arterial pressure | LAZ Year 2 | 1406 | 60.89 | 68.86 | -1.53 | -1.49 | 0.04 (-0.03, 0.11) | 0.23 |
|  | WAZ Year 2 | 1407 | 60.83 | 68.83 | -1.74 | -1.71 | 0.02 (-0.08, 0.12) | 0.66 |
|  | WLZ Year 2 | 1430 | 60.78 | 68.78 | -1.25 | -1.21 | 0.04 (-0.07, 0.16) | 0.45 |
|  | HCZ Year 2 | 1487 | 60.78 | 68.67 | -1.52 | -1.5 | 0.02 (-0.02, 0.06) | 0.24 |
|  |  |  |  |  |  |  |  |  |
| Mean resting heart rate | LAZ Year 2 | 1409 | 99.33 | 118.67 | -1.53 | -1.52 | 0.01 (-0.03, 0.05) | 0.56 |
|  | WAZ Year 2 | 1410 | 99.33 | 118.67 | -1.73 | -1.72 | 0.01 (-0.03, 0.05) | 0.66 |
|  | WLZ Year 2 | 1433 | 99.33 | 118.67 | -1.25 | -1.25 | 0 (-0.05, 0.05) | 0.96 |
|  | HCZ Year 2 | 1488 | 99.33 | 118.67 | -1.55 | -1.5 | 0.05 (0, 0.09) | 0.07 |
| N, 25th Percentile, and 75th Percentile are from the adjusted analyses | | | | | | | | |
| \* P-value < 0.05 after FDR correction (\*\* P-value < 0.01, \*\*\* P-value < 0.001) | | | | | | | | |

## Table S7: Associations between methylation and growth measures at 28 months

| Methylation site | Outcome | N | 25th Percentile | 75th Percentile | Outcome, 75th Percentile v. 25th Percentile | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  | Predicted Outcome at 25th Percentile | Predicted Outcome at 75th Percentile | Coefficient (95% CI) | P-value |
| Entire promoter region (39 assayed CpG sites) | LAZ Year 2 | 660 | -6.05 | -5.31 | -1.5 | -1.54 | -0.04 (-0.15, 0.08) | 0.56 |
|  | WAZ Year 2 | 660 | -6.05 | -5.31 | -1.8 | -1.81 | -0.01 (-0.13, 0.11) | 0.89 |
|  | WLZ Year 2 | 670 | -6.06 | -5.32 | -1.12 | -1.1 | 0.03 (-0.08, 0.13) | 0.64 |
|  | HCZ Year 2 | 692 | -6.05 | -5.31 | -1.67 | -1.67 | 0 (-0.05, 0.05) | 0.97 |
|  |  |  |  |  |  |  |  |  |
| NGFI-A transcription factor binding site (CpG site #12) | LAZ Year 2 | 395 | -4.65 | -4.15 | -1.35 | -1.35 | 0 (-0.06, 0.07) | 0.93 |
|  | WAZ Year 2 | 395 | -4.65 | -4.15 | -1.93 | -1.9 | 0.02 (-0.15, 0.2) | 0.8 |
|  | WLZ Year 2 | 399 | -4.65 | -4.15 | -1.29 | -1.23 | 0.06 (-0.15, 0.26) | 0.59 |
|  | HCZ Year 2 | 413 | -4.65 | -4.14 | -1.68 | -1.68 | 0 (-0.07, 0.07) | 0.96 |
| N, 25th Percentile, and 75th Percentile are from the adjusted analyses | | | | | | | | |
| \* P-value < 0.05 after FDR correction (\*\* P-value < 0.01, \*\*\* P-value < 0.001) | | | | | | | | |